Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
Clin Drug Investig. 2023 Sep;43(9):707-708.
doi: 10.1007/s40261-023-01305-3.